Showing 4201-4210 of 5646 results for "".
- NIH Study Confirms Benefit of Supplements for Slowing AMDhttps://modernod.com/news/nih-study-confirms-benefit-of-supplements-for-slowing-age-related-macular-degeneration-amd/2480894/The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), according to the Nationa
- Apellis Submits New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophyhttps://modernod.com/news/apellis-announces-submission-of-nda-to-the-fda-for-pegcetacoplan-for-geographic-atrophy/2480890/Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- "Artificial Intelligence in Ophthalmology 2022" Conference is Being Held Onlinehttps://modernod.com/news/artificial-intelligence-in-ophthalmology-2022-conference-is-being-held-online/2480884/The "Artificial Intelligence in Ophthalmology 2022" conference is being held online on June 3, 2022. The conference will feature an overview of artificial intelligence (AI), machine learning (ML) and deep learning (
- AMA: Health Insurance Industry Continues to Falter on Prior Authorization Reformhttps://modernod.com/news/ama-health-insurance-industry-continues-to-falter-on-prior-authorization-reform/2480880/Despite mounting evidence that insurer-imposed authorizations for drugs and medical services can be a hazardous and burdensome administrative obstacle to patient-centered care, the health insurer industry continues to show apathetic or ineffectual follow-through on mutually accepted reforms, acco
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- New Study Highlights Patient Willingness to Adhere to Pre-Op Prephttps://modernod.com/news/new-study-highlights-patient-willingness-to-adhere-to-pre-op-prep/2480874/Bruder Healthcare announced new research that supports cataract surgeons and comanaging optometrists and ophthalmologists as they help patients prepare for surgery. This noninterventional, cross-sectional investigation of 278 US adults age 65 and older sought to identify cataract s
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol Eye Drops for Night Vision Disturbanceshttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances/2480873/Ocuphire Pharma announced positive topline results from the LYNX-1 phase 3 pivotal clinical trial investigating its product candidate Nyxol for night (or dim light) vision disturbances (NVD). More than 650 subjects have now been exposed to Nyxol. NVD is a condition i
- Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officerhttps://modernod.com/news/visiox-pharma-appoints-ryan-s-bleeks-as-chief-executive-officer/2480872/Visiox Pharma announced the appointment of Ryan S. Bleeks as Chief Executive Officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His
- 2022 Bressler Prize Awarded to Dr. Sheila Nirenberg for Outstanding Accomplishments in Vision Sciencehttps://modernod.com/news/2022-bressler-prize-awarded-to-dr-sheila-nirenberg-for-outstanding-accomplishments-in-vision-science/2480866/Not-for-profit Lighthouse Guild announced today that Sheila Nirenberg, PhD, has been awarded the 2022 Bressler Prize for her outstanding advances in vision science, including deciphering the retina’s neural code which is the key to restoring meaningful vision in people who are blind fr